Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Trial for Prostate Cancer

This study has been completed.
Information provided by:
Oakwood Laboratories, LLC Identifier:
First received: January 26, 2004
Last updated: January 24, 2008
Last verified: January 2008
Phase III trial using an injectable for treatment of prostate cancer.

Condition Intervention Phase
Prostate Cancer
Drug: Leuprolide Acetate for Injectable Suspension 22.5 mg
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Oakwood Laboratories, LLC:

Study Start Date: December 2003
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00076531

Sponsors and Collaborators
Oakwood Laboratories, LLC
Study Chair: James A. Page, M.D. Oakwood Laboratories, LLC
  More Information

Additional Information: Identifier: NCT00076531     History of Changes
Other Study ID Numbers: OL-007 
Study First Received: January 26, 2004
Last Updated: January 24, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Oakwood Laboratories, LLC:

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on October 21, 2016